Low ZHX2 is associated with poor prognosis in chronic lymphocytic leukemia and multiple myeloma (MM) (8, 54), while higher ZHX2 mRNA correlates with better overall survival in patients with breast cancer (55) and thyroid cancer (7). Here, ZHX2 is linked to AL amyloidosis.